AEterna Zentaris (AEZS) : Analyst Rating Update

AEterna Zentaris (AEZS) : 3 brokerage houses believe that AEterna Zentaris (AEZS) is a Strong Buy at current levels. 1 Analyst considers the fundamentals to be worthy of a Buy recommendation. Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 4 Wall Street Analysts endorse the stock as a Strong Buy with a rating of 1.25.

AEterna Zentaris (AEZS) stock is expected to deviate a maximum of $0.82 from the average target price of $11 for the short term period. 4 Street Experts have initiated coverage on the stock with the most promising target being $12 and the most muted being $10.

AEterna Zentaris (NASDAQ:AEZS): The stock opened at $3.38 on Wednesday but the bulls could not build on the opening and the stock topped out at $3.49 for the day. The stock traded down to $3.30 during the day, due to lack of any buying support eventually closed down at $3.35 with a loss of -1.18% for the day. The stock had closed at $3.39 on the previous day. The total traded volume was 259,818 shares.

The company shares have dropped -85.88% from its 1 Year high price. On Jul 14, 2015, the shares registered one year high at $25.00 and the one year low was seen on Jan 15, 2016. The 50-Day Moving Average price is $3.44 and the 200 Day Moving Average price is recorded at $3.54.

Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company engaged in developing treatments in oncology, endocrinology and womens health. The Company has three wholly owned direct and indirect subsidiaries: AEZS GmbH, based in Frankfurt, Germany, Zentaris IVF GmbH, a direct wholly owned subsidiary of AEZS Germany based in Frankfurt, Germany, and Aeterna Zentaris, Inc. Its drug development efforts are focused on two compounds, zoptarelin doxorubicin and Macrilen, which are in clinical development, and on two oncology compounds (an Erk inhibitor and Luteinizing Hormone-Releasing Hormone-disorazol Z product candidates), which are in pre-clinical development. Zoptarelin doxorubicin represents a hybrid molecule composed of a synthetic peptide carrier and a chemotherapy agent, doxorubicin. Macrilen (macimorelin acetate) is an orally available peptidomimetic ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the ghrelin receptor.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.